Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

United Therapeutics (UTHR) Prepaid Assets (2016 - 2025)

Historic Prepaid Assets for United Therapeutics (UTHR) over the last 17 years, with Q3 2025 value amounting to $252.2 million.

  • United Therapeutics' Prepaid Assets rose 3603.02% to $252.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $252.2 million, marking a year-over-year increase of 3603.02%. This contributed to the annual value of $169.7 million for FY2024, which is 210.59% up from last year.
  • As of Q3 2025, United Therapeutics' Prepaid Assets stood at $252.2 million, which was up 3603.02% from $229.7 million recorded in Q2 2025.
  • In the past 5 years, United Therapeutics' Prepaid Assets registered a high of $252.2 million during Q3 2025, and its lowest value of $49.7 million during Q1 2021.
  • Moreover, its 5-year median value for Prepaid Assets was $158.4 million (2023), whereas its average is $148.2 million.
  • In the last 5 years, United Therapeutics' Prepaid Assets surged by 11832.67% in 2022 and then crashed by 2417.88% in 2023.
  • Over the past 5 years, United Therapeutics' Prepaid Assets (Quarter) stood at $100.4 million in 2021, then surged by 118.33% to $219.2 million in 2022, then fell by 24.18% to $166.2 million in 2023, then rose by 2.11% to $169.7 million in 2024, then skyrocketed by 48.62% to $252.2 million in 2025.
  • Its Prepaid Assets stands at $252.2 million for Q3 2025, versus $229.7 million for Q2 2025 and $131.1 million for Q1 2025.